Trends in Pharmacological Sciences
OpinionIn vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant
Section snippets
Optimization of In Vivo Drug–Target Binding Kinetics for Drug Discovery
To optimize the duration of drug action for therapeutic use, developers have primarily focused on modification of pharmacokinetic (see Glossary) parameters. However, an alternative approach is to optimize the duration of drug action by the modification of drug–target binding kinetics.
The target association and dissociation rate constants are important determinants of both the time course and the extent of drug effects and their values can be measured in high-throughput in vitro systems (Box 1).
Drug–Target Binding In Vivo: Where Does It Occur?
The commonly used mathematical models for drug–target binding were analyzed in this study to yield a quantitative insight into the relative impact of drug–target binding kinetics and pharmacokinetics on the time course of target occupancy in vivo. The simplest model considers the situation where drug–target binding and elimination of the unbound drug from the blood or from a tissue that is in fast equilibrium with the blood occur simultaneously. This is schematically represented by Model 1 (
Simultaneous Elimination and Drug–Target Binding: What Is the Difference?
The influence of pharmacokinetics on the role of drug–target binding kinetics has been acknowledged previously. This influence has been summarized in the general paradigm that the rate of drug–target dissociation has to be slower than the rate of elimination of the unbound drug to prolong the duration of target occupancy. However, this general rule does not take into account the possible influence of drug–target binding on unbound drug concentration profiles. The influence of drug–target
Is the Impact of Drug–Target Binding Kinetics Different for Target Binding in a Tissue?
To expand our understanding of drug–target binding, an analysis similar to that conducted for drug–target binding in the blood was performed for drugs that bind only in a specific tissue. The results of this analysis can be found in S3 in the supplemental information online. One of the main differences compared with the analysis for Model 1 is that the drug distribution from the tissue to the central compartment can be rate limiting for Model 2. A high value of kon leads to equal impacts of kon
Optimizing Drug–Target Binding Kinetics: To What End?
For drug–target binding in both plasma and tissue, our analysis indicates that high kon values can decrease the target occupancy decline below the elimination and dissociation rates. However, this increased duration of target occupancy is caused by increased local drug concentrations unless both koff and kon are low. This means that the optimal value for kon depends on the target, the drug class, and the drug-specific pharmacokinetic, pharmacodynamic, and toxicity processes.
If an increased
Concluding Remarks
Comprehensive analysis of the commonly used models for drug–target binding reveals that high drug–target association rate constants result in longer target occupancy than expected on the basis of the drug–target dissociation and drug elimination rate constants. The kon value that separates high and low values of kon increases with increasing target concentration and with decreasing drug elimination and distribution rate constants and can be calculated algebraically. High values of kon, for
Acknowledgments
The authors thank Professor L.A. Peletier for critically reading the manuscript and providing useful feedback. The authors are part of the K4DD consortium, which is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement no 115366. The IMI JU is a project supported by the EU's Seventh Framework Programme (FP7/2007–2013) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Glossary
- Endogenous competition
- binding of an endogenous ligand to the same binding site as a drug.
- Endogenous ligand
- a compound that is naturally present in the body and functions by binding to a certain receptor.
- Kinetic selectivity
- differential kinetics of a compound for binding to intended and unintended targets. Most often considered beneficial if the residence time on the intended target is longer than the residence time on the unintended target.
- Nonspecific binding
- drug binding to proteins, lipids, or
References (39)
- et al.
Pharmacokinetics and the drug–target residence time concept
Drug Discov. Today
(2013) Mathematical analysis of the pharmacokinetic–pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency
J. Theor. Biol.
(2011)- et al.
Effects of the geometry of the immunological synapse on the delivery of effector molecules
Biophys. J.
(2004) Opiate antagonist receptor binding in vivo: evidence for a new receptor binding model
Brain Res.
(1980)Equilibrium and kinetic selectivity profiling on the human adenosine receptors
Biochem. Pharmacol.
(2016)- et al.
Approximating the effects of diffusion on reversible reactions at the cell surface: ligand–receptor kinetics
Biophys. J.
(1995) Drug–target residence time and its implications for lead optimization
Nat. Rev. Drug Discov.
(2006)Back to basics: label-free technologies for small molecule screening
Comb. Chem. High Throughput Screen.
(2008)The role of binding kinetics in therapeutically useful drug action
Curr. Opin. Drug Discov. Devel.
(2009)Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia
J. Pharmacol. Exp. Ther.
(2012)
Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?. A new hypothesis
Am. J. Psychiatry
Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor
Mol. Pharmacol.
Investigating the molecular mechanisms through which FTY720-P causes persistent S1P1 receptor internalization
Br. J. Pharmacol.
The dynamics of drug–target interactions: drug–target residence time and its impact on efficacy and safety
Expert Opin. Drug Discov.
Drug–target residence time – a case for G protein-coupled receptors
Med. Res. Rev.
Mechanistic models enable the rational use of in vitro drug–target binding kinetics for better drug effects in patients
Expert Opin. Drug Discov.
A new generalized nonlinear pharmacokinetic model and its implications
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
J. Pharmacokinet. Pharmacodyn.
A tutorial on target-mediated drug disposition (TMDD) models
CPT Pharmacometrics Syst. Pharmacol.
Cited by (91)
Folic acid-decorated alginate nanoparticles loaded hydrogel for the oral delivery of diferourylmethane in colorectal cancer
2023, International Journal of Biological MacromoleculesChitosan/guar gum-based thermoreversible hydrogels loaded with pullulan nanoparticles for enhanced nose-to-brain drug delivery
2022, International Journal of Biological MacromoleculesFolic acid-functionalized nanoparticles-laden biomaterials for the improved oral delivery of hydrophobic drug in colorectal cancer
2022, Journal of Drug Delivery Science and TechnologyNanomedicine for brain cancer
2022, Advanced Drug Delivery Reviews